Danielle Ralic
CEO
Ancora provides an AI-driven platform that matches cancer patients with relevant clinical trials based on their diagnosis, location, and preferences. Users can quickly search, refine results through a brief questionnaire, and track enrollment progress within a secure, HIPAA- and GDPR-compliant dashboard. The service is free, offering personalized trial alerts and the ability to share profiles with trial sites while maintaining strict privacy controls.
Raised to date
$520KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CEO
Patient enrollment in clinical trials is often slow and inefficient due to difficulties in matching eligible patients with suitable studies. Many trials face delays or even termination because they cannot recruit enough participants, hindering medical advancements.
Ancora.ai is an AI-powered platform designed to streamline patient matching and recruitment for clinical trials. The platform analyzes patient medical profiles and preferences to identify relevant clinical trials, accelerating the enrollment process. By improving the precision of patient-trial matching, Ancora.ai helps clinical research organizations overcome recruitment bottlenecks and accelerate the development of new therapies. The platform aims to enhance the efficiency of clinical trials, ensuring that promising treatments reach patients faster.
The primary target audience includes clinical research organizations (CROs), pharmaceutical companies, and academic medical centers conducting clinical trials.